Abstract
Background Dengue and Chikungunya are Aedes-borne diseases that are predominantly prevalent in tropical and subtropical regions, affecting public health globally. Dengue is caused by multiple antigenically different Dengue virus (DENV) serotypes (DENV-1 to DENV 4) in the Flaviviridae family and Chikungunya (CHIKV) in the Togaviridae family. Both viral diseases produce similar clinical manifestations, especially in the early stages of infection which poses a significant challenge for timely diagnosis and improper disease management. In India, diagnosis of Dengue and Chikungunya relies on ELISA-based tests, which often lead to false negatives and under estimation of the disease burden.
Methods A multiplex, quantitative, real-time PCR assay, DENCHIK was developed for simultaneous detection of DENV serotypes and CHIKV.A total of 903 sera samples were screened from suspected febrile patients across 161 public health centers in Bengaluru, between July 2022 - December 2022. The sensitivity and specificity of DENCHIK assay was compared with ELISA (NS1 antigen and Immunoglobulin M (IgM) antibodies) and two commercially available q RT-PCR assays for DENV and CHIKV.
Findings Using DENCHIK assay,36% infections were DENV, 17% CHIKV and 8% were DENV CHIKV co-infections. In contrast, ELISA detected 29.90% of DENV and 22.92% of CHIKV infections. We observed 9% prevalence of DENV infections using NS1 ELISA as compared to 24% by IgM ELISA. DENV-1 was the predominant serotype followed by DENV-2, DENV-3 and DENV-4. There was an increase in the prevalence of DENV and CHIKV infections from June to September 2022, coinciding with the monsoon season. There was no significant difference observed in the prevalence of DENV and CHIKV infections across genders and ages. The sensitivity and specificity of DENCHIK assay in DENV detection as compared to NS1 ELISA assay was observed to be 62.82% and 66.45%, respectively. In comparison to commercially available q RT-PCR assays for DENV detection, DENCHIK assay exhibited 99% and 98% sensitivity and specificity, respectively. Similarly, in case of CHIKV 26% sensitivity, 86% specificity and 98% sensitivity and specificity were observed, as compared to the IgM ELISA and commercial RT-PCR assays, respectively.
Conclusion DENCHIK assay successfully enabled, simultaneous amplification of all four DENV serotypes and Chikungunya, from clinical samples. DENCHIK assay detected 7.6% of additional Dengue infections and 6.65% less of Chikungunya infections in clinical samples, as compared to detection by ELISA. As, compared to ELISA, DENCHIK demonstrates early and accurate detection of DENV and CHIKV with higher sensitivity and specificity, as early as day one of symptom onset post infection. DENCHIK aids in estimating the exact prevalence of DENV and CHIKV infections, that are often misdiagnosed, using ELISA. Molecular surveillance using targeted diagnostic assays such as DENCHIK could be used to determine the prevalence of multiple DENV serotypes, CHIKV and DENV-CHIKV Co-infections from clinical samples. The findings from the study shall be useful to inform and aid the public health authorities, to contain and curb the rapid spread of these diseases in the community.
Author Summary Dengue and Chikungunya are most common arboviral illnesses affecting more than half of the world’s population. Both the viral diseases have overlapping symptoms, which poses a challenge for accurate differential diagnostics in low-resource setting. Infection with one or more different serotypes of DENV results in a phenomenon, known as antibody-dependent enhancement (ADE), wherein antibodies against one serotype, instead of protecting against DENV infection caused by other serotypes, aids in the viral uptake by the host immune cells, resulting in severe dengue.
Rapid antigen tests targeting NS1, and IgG/IgM are the most common methods used to detect DENV and CHIKV infections. However, there are several limitations of serological assays: a) ELISA cannot differentiate DENV serotypes, b) depending on the stage of infection, ELISA-based tests often provide false-positives or false-negatives. This warrants a need for a reliable molecular method which can differentiate between DENV serotypes and across Dengue and Chikungunya with reasonable sensitivity and specificity.
Bengaluru has highest dengue burden in Southern India. There is high infestation of Aedes aegypti and Aedes albopictus in diverse breeding habitat and year-round circulation of four serotypes. Currently, Dengue and Chikungunya testing relies on ELISA (NS1, IgM and IgG) often leading to under estimation of disease burden. To address this gap, a cost-effective multiplex qRT-PCR assay, DENCHIK was developed for simultaneous detection of four DENV serotypes and CHIKV. The sensitivity and specificity of DENCHIK assay was tested across months and days from onset of febrile symptoms and compared with ELISA and two commercially available kits. We suggest implementation of molecular methods and using DENCHIK assay in urban health centres would help reduce underestimation of cases, actual estimates of disease burden across seasons and help in better clinical management of Dengue and Chikungunya.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study is financially supported by Tata Trusts funding to Tata Institute for Genetics and Society. We didnt receive funding from any other funding agency for this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Institutional Human Ethics Committee, Institute for Stem Cell and Regenerative Medicine, Department of Biotechnology, Government of India (Reference number: inStem/IEC-26/04N) and Ethics Committee of Bangalore Medical College and Research Institute, Bangalore, Karnataka (Reference no: BMCRI/PS/41/2022-23).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All the data pertaining to the manuscript findings has been included with the submission.
